ViiV Healthcare receives approval from China’s National Medical Products Administration for Vocabria (cabotegravir) used in combination with Rekambys (rilpivirine), the first and only complete long-acting HIV-1 injectable treatment
— The marketing authorisation for rilpivirine long-acting injection was received on the 18 October 2023
— The complete long-acting regimen enables people living with HIV in China, who are virologically suppressed to reduce the treatment dosing days from 365 to 12 or 6 per year after initiation
— With an estimated 1.045 million people living with HIV in China expanding treatment options is critical to reduce the scale of the epidemic in the country
Read the full press release here.
Source : ViiV Healthcare
Related HIV and Co-Infections News
-
[Press release] FDA grants priority review of New Drug Application for Gilead’s once-daily HIV treatment of bictegravir plus lenacapavir
-
[CROI 2026] HIV i-Base: Investigational HIV combinations – daily, weekly, 4- and 6-monthly…
-
[Press release] FDA approves Merck’s once-daily IDVYNSO™ (doravirine/islatravir)
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.